Glucokinase activators: A glucose sensor role in pancreatic islets and hepatocyte

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue 2, 2012, Pages 81-87

  Priyadarsini, R L ^a   Risy Namratha, J ^a   Ravi Sankar Reddy, D ^a  

^a ACHARYA NAGARJUNA UNIVERSITY   (India)

Author keywords

GK (Glucokinase); Homeostasis; Type II diabetes

Indexed keywords

2 [2 [3 (4 TERT BUTYL CYCLOHEXYL) 3 CYCLOHEXYLUREIDO]THIAZOL 5 YLSULFANYL] 2 METHYLPROPIONIC ACID; 3 [2 [3 (4 TERT BUTYL CYCLOHEXYL) 3 CYCLOPENTYLUREIDO]THIAZOL 5 YLSULFANYL]PROPIONIC ACID; [2 [3 CYCLOHEPTYL 3 (4 METHOXYCYCLOHEXYL)UREIDO]THIAZOL 5 YLSULFANYL]ACETIC ACID; ADRENALIN; ANTIDIABETIC AGENT; GLUCAGON; GLUCOKINASE; GLUCOKINASE ACTIVATOR; GLUCOSE; GROWTH HORMONE; HEXOKINASE; HYDROCORTISONE; INSULIN; ISOENZYME; UNCLASSIFIED DRUG;

AUTONOMIC NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM; CHOLINERGIC NERVE CELL; CHROMAFFIN CELL; DRUG MECHANISM; DRUG TARGETING; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HORMONE RELEASE; HUMAN; INSULIN RELEASE; LIVER CELL; LIVER CLEARANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REVIEW;

EID: 84859938197     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Dr. AVSS Rama Rao, Enzymes 4th edition. p 160-161, 180-183.
2. rd edition. p 246-247,
3. Cardenas, M.L., Cornish-Bowden, A., and Ureta, T. Evolution and regulatory role of the hexokinases. Biochim. Biophys. Acta 1998 1; 401: 242-264.
4. Rother KI. Diabetes treatment-bridging the device. The new England journal of medicine Aprial 2007; 356(15)1:499-501.
5. Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetesand gestational diabetesmellitus among a racially / ethnically diverse population ofa prgnent women. Diabetis care; 1999-2005: 31(5): 899-904.
6. Cooke DW, Plotnick L(Nov 2008). Type Idiabetes mellitus inpediatrics. Pediatre Rev 299(11):374-84.
7. American Diabetes Association: Standards of medical care in diabetes-2006. Diabetes Care29 (Suppl. 1):S4-42, 2006.
8. Cardenas, M.L. (2004). Comparative biochemistry of glucokinase. Glucokinase And Glycemic Disease: From Basics to Novel Therapeutics (Frontiers in Diabetes). Basel: S. Karger AG (Switzerland). 2004; 31-41.
9. Magnuson, M.A. Matschinsky, F.M. Glucokinase as a glucose sensor: past, present, and future. Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics (Frontiers in Diabetes). Basel: S. Karger AG (Switzerland).2004; 18-30.
10. Iynedjian PB. Molecular physiology of mammalian glucokinase. Cell. Mol. Life Sci; 2009: 66 (1): 27-42.
11. Cardenas, M.L. Comparative biochemistry of glucokinase. Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics (Frontiers in Diabetes). Basel: S. Karger AG (Switzerland); 2004: pp. 31-41.
12. Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure. 2004; 12:429-38.
13. Ronimus RS, Morgan HW. Cloning and biochemical characterization of a novel mouse ADP-dependent glucokinase. Biochem. Biophys. Res. Commun.; 2004: 315 (3): 652-8.
14. Magnuson, M.A.; Matschinsky, F.M. Glucokinase as a glucose sensor: past, present, and future. Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics (Frontiers in Diabetes). Basel: S. Karger AG (Switzerland); 2004: 18-30.
15. Bell, G.I.; Cuesta-Munoz, A.; Matschinsky, F.M. Glucokinase. Encyclopedia of Molecular Medicine. Hoboken: John Wiley & Sons; 2202
16. Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure. 2004;12:429-38
17. Matschinsky FM: Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov. 2009, 8: 399-416.
18. Agius L: Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J. 2008, 414:1-18
19. Del Guerra S, Lupi R, Marselli L, Masini M, Bugliani M, Sbrana S, Torri S, Polera M, Boggi U: Functional and molecular defects of pancreatic islets in type 2 diabetes. Diabetes. 2005, 54:727-35.
20. Pal M: Recent advances in glucokinase activators for treatment of type 2 diabetes. Drug Discovery Today; 2009, 14:784-92.
21. Coghlan M, Leighton B: Glucokinase activators in diabetes management. Expert Opin Investig Drugs; 2008, 17:145-67.
22. Guertin KR, Grimsby J: Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. Curr Med Chem; 2006, 13:1839-43.
23. Sarabu R, Berthel SJ, Kester RF, Tilley JW: Glucokinase activators as new type 2 diabetes therapeutic agents. Expert Opin Ther Pat; 2008, 18:759-68.
24. Sarabu R, Grimsby J: Targeting glucokinase activation for the treatment of type 2 diabetes - a status review. Curr Opin Drug Discov Devel; 2005, 8:631-7.
25. Matschinsky FM: Banting Lecture. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes. 1996, 45:223-41.
26. Baltrusch S, Wu C, Okar DA, Tiedge M, Lange AJ: Edited by Matschinsky FM, Magnuson MA, Glucokinase and Glycemic Disease: From Basics to Novel Therapeutics. Front Diabetes; 2004, 16:262-74.
27. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of general amber force field. J Comput Chem; 2004; 25(9):1157-74.
28. Matschinsky FM: Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov; 2009, 8:399-416.
29. Grimsby J, Sarabu R, Corbett WL, Haynes N, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF: Allosteric activators of glucokinase: potential role in diabetes therapy. Science; 2003, 301:370-3.
30. Pal M: Recent advances in glucokinase activators for treatment of type 2 diabetes. Drug Discovery Today; 2009, 14:784-92.
31. Zhi J, Zhai S, Mulligan ME, Grimsby J, Arbet-Engels C, Boldrin M, Balena R: A novel glucokinase activator RO4389620 improved fasting and postprandial plasma glucose in type 2 diabetic patients. Diabetologia; 2008, 51 (Suppl Suppl 1):S23
32. Bonadonna RC, Kapitza C, Heinse T, Avogaro A, Boldrin M, Grimsby J, Mulligan ME, Arbet-Engles C, Balena R: Glucokinase activator RO4389620 improves beta cell function and plasma glucose indexes in patients with type 2 diabetes. Diabetologia. 2008, 51 (Suppl Suppl 1):S371.
33. Zhai S, Mulligan ME, Grimsby J, Arbet-Engels C, Boldrin M, Balena R, Zhi J: Phase I assessment of a novel glucose activator RO4389620 in healthy male volunteers. Diabetologia. 2008, 51 (Suppl Suppl 1):S372
34. Huey R, Morris GM, Olson AJ, Goodsell DS. An empirical free energy force field with charge-based desolvation and intramolecular evaluation. J Comp Chem. 2007; 28:1145-1152.
35. Morris GM, Goodsell DS, Halliday RS, et al. Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. J Comput Chem; 1998; 19:1639-62.
36. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci US;. 2001; 98:10037-41.
37. Guesrtin KR, Grimsby J: Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. Curr Med Chem; 2006, 13:1839-43.
38. Sarabu R, Berthel SJ, Kester RF, Tilley JW: Glucokinase activators as new type 2 diabetes therapeutic agents. Expert Opin Ther Pat; 2008, 18:759-68.
39. Li C, Liu C, Nissim I, et al. The role of glycine and gammahydoxybutyrate in the regulation of glucagon secretion in human islets. 2009 Spring Symposium and Kroc Lecture, University of Pennsylvania, 11 March 2009.
40. Agius L The physiological role of glucokinase binding and translocation in hepatocytes. Adv Enzyme Regul 1998; 38:303-331.
41. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008; 414:1-18.
42. A, Van Schaftingen E. The mechanism by which rat liver glucokinase is inhibited by the regulatory protein. Eur J Biochem 1990; 191:483-489.
43. Competitive inhibition of liver glucokinase by its regulatory protein. Eur J Biochem 1991; 200:545-551pmid:188941.
44. Detheux M,. Effectors of the regulatory protein acting on liver glucokinase: a kinetic investigation. Eur J Biochem; 1991; 200:553-561.
45. Veiga-da-Cunha M, Van Schaftingen E. Identification of fructose 6-phosphate- and fructose 1-phosphate-binding residues in the regulatory protein of glucokinase. J Biol Chem 2002; 277:8466-847.
46. Gromada J, Franklin I, Wollheim CB. "α-cells of the endocrine pancreas: 35 years of research but the enigma remains". 2007; 28:84-116.